Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...

Chugai Pharmaceutical has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular ...

Iron-dependent ferroptosis, a non-apoptotic cell death mechanism, is gaining attention for its role in immune suppression.

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...

The author of the ‘Leonard List’ that highlights emerging hematologic research to be presented at annual ASH meetings is also ...

Specific vitamins and nutrients can help boost the hair growth cycle and support optimum growth. However, vitamin ...

HALIFAX — Nova Scotia still hasn’t signed on to the federal government’s pharmacare plan, and the province’s Opposition New ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

The stent hadn’t helped after all; the impacted kidney had, in fact, been irreversibly damaged and was now functioning at a ...